

## Technology Appraisal Committee Meeting (Committee B)

**Minutes:** Confirmed

**Date and Time:** Tuesday 10 July 2018, from 10am to 1pm

**Venue:** 10 Spring Gardens  
London  
SW1A 2BU

**Present:**

1. Dr Amanda Adler (Chair)	Present for all notes
2. Dr Sanjeev Patel (Vice Chair)	Present for all notes
3. Mr Mark Chapman	Present for all notes
4. Professor John Cairns	Present for all notes
5. Mr Diar Fattah	Present for all notes
6. Ms Susan Faulds	Present for all notes
7. Dr Mark Glover	Present for all notes
8. Mr Richard Hoddes	Present for all notes
9. Dr Mona Johnson	Present for all notes
10. Dr Sanjay Kinra	Present for all notes
11. Dr Nicholas Latimer	Present for all notes
12. Mr Christopher O'Regan	Present for notes 1 to 16
13. Dr Stephen Smith	Present for all notes
14. Mr William Turner	Present for all notes
15. Mr Nigel Westwood	Present for all notes
16. Professor Sarah Wild	Present for all notes

### In attendance:

Mirella Marlow	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Dr Melinda Goodall	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Jeremy Powell	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Sandra Aleknavice	Administrator, National Institute for Health and Care Excellence	Present for all notes
Jessica Cronshaw	Technical Analyst, National Institute for Health and Care	Present for notes 1 to 16

## Excellence

Ross Dent	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 1 to 16
Alan Lamb	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 17 to 30
Ahmed Elsada	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 17 to 30
Professor Peter Clark	Chair of NHS England Chemotherapy Clinical Reference Group and National Clinical Lead for CDF	Present for all notes
Dr Miriam Brazzelli	Senior Research Fellow, Aberdeen HTA Group	Present for notes 1 to 13
Dr Ewen Cummins	Health Economist, Aberdeen HTA Group	Present for notes 1 to 13
Professor Joanne Lord	Director and Professorial Fellow, Southampton Health Technology Assessment Centre	Present for notes 17 to 28
Dr Jonathan Shepherd	Principal Research Fellow, Southampton Health Technology Assessment Centre	Present for notes 17 to 28

## Non-public attendees:

Aalya Al-Assaf	NIHR Innovation Observatory	Present for all notes
Helen Barnett	Medical Editor, NICE	Present for all notes
Chloe Kastoryano	PIP, NICE Medical Editor, NICE	Present for all notes
Edgar Masanga	Business Analyst, NICE	Present for all notes
Rebecca Smittenaar	Public Health England	Present for all notes
Dr Alice Turnbull	Public Health England	Present for all notes

## Notes

### Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of abiraterone for treating newly diagnosed metastatic hormone-naive prostate cancer [ID945] and cabozantinib for untreated

metastatic renal cell carcinoma [ID1208].

2. The Chair informed the Committee of the non-public observers at this meeting: Aalya Al-Assaf, Helen Barnett, Chloe Kastoryano, Edgar Masanga, Rebecca Smittenaar and Dr Alice Turnbull.
3. Apologies were received from Professor Stephen Palmer, Professor Nicky Welton and Dr Stuart Williams.

### **Any other Business**

4. The Committee were given an update on the progress of other appraisals previously seen by the Committee and an update on personnel changes within the NICE Technology Appraisals team.

### **Appraisal of abiraterone for treating newly diagnosed metastatic hormone-naive prostate cancer [ID945]**

#### **Part 1 – Open session**

5. The Chair welcomed the invited experts: Professor Peter Clark, Dr Miriam Brazzelli and Dr Ewen Cummins to the meeting and they introduced themselves to the Committee.
6. The Chair welcomed company representatives from Janssen to the meeting.
7. The Chair asked all Committee members to declare any relevant interests
  - 7.1. Dr Amanda Adler, Dr Sanjeev Patel, Mr Mark Chapman, Professor John Cairns, Mr Diar Fattah, Ms Susan Faulds, Dr Mark Glover, Mr Richard Hoddes, Dr Mona Johnson, Dr Sanjay Kinra, Mr Christopher O'Regan, Dr Stephen Smith, Mr William Turner, Mr Nigel Westwood and Professor Sarah Wild all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of abiraterone for treating newly diagnosed metastatic hormone-naive prostate cancer [ID945].
  - 7.2. Dr Nicholas Latimer declared that he had received a consultancy fee from Janssen for providing a half-day training course on survival analysis. He also declared that he had received a consultancy fee from Astra Zeneca for giving advice on survival modelling for durvalumab as a monotherapy among patients with stage IIIB–IV NSCLC.
    - 7.2.1. It was agreed that as this declaration did not relate to the intervention product or to a specific comparator product Dr Latimer could participate in this section of the meeting.
8. The Chair asked all NICE Staff to declare any relevant interests.
  - 8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of abiraterone for

treating newly diagnosed metastatic hormone-naive prostate cancer [ID945].

9. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
  - 9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of abiraterone for treating newly diagnosed metastatic hormone-naive prostate cancer [ID945].
10. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
12. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
13. The Chair then thanked the company representatives and Evidence Review Group representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

## **Part 2 – Closed session**

14. Discussion on confidential information continued. This information was supplied by the company.
15. The Committee continued to discuss the clinical and cost effectiveness of abiraterone for treating newly diagnosed metastatic hormone-naive prostate cancer [ID945].
  - 15.1. The committee decision was based on consensus.
16. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

## **Notes from the last meeting**

17. The minutes of the Committee meetings held on 10 May 2018 and 6 June 2018 were approved.

## **Appraisal of cabozantinib for untreated metastatic renal cell carcinoma [ID1208]**

### **Part 1 – Open session**

18. The Chair welcomed the invited experts: Professor Peter Clark, Professor Joanne Lord and Dr Jonathan Shepherd to the meeting and they introduced themselves to the Committee.
19. The Chair welcomed company representatives from Ipsen to the meeting.
20. The Chair asked all Committee members to declare any relevant interests
  - 20.1. Dr Amanda Adler, Dr Sanjeev Patel, Mr Mark Chapman, Mr Diar Fattah, Ms Susan Faulds, Dr Mark Glover, Mr Richard Hoddes, Dr Mona Johnson, Dr Sanjay Kinra, Dr Stephen Smith, Mr William Turner, Mr Nigel Westwood and Professor Sarah Wildd all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cabozantinib for untreated metastatic renal cell carcinoma [ID1208].
  - 20.2. Professor John Cairns declared before the meeting that he has received payment for participating in an MCDA workshop organised by the LSE and funded by Novartis. The focus was on the MCDA method and not on a specific Novartis product.
    - 20.2.1. It was agreed that this declaration would not prevent Professor Cairns from participating in this section of the meeting.
  - 20.3. Dr Nicholas Latimer declared that he had received consultancy fees from Pfizer relating to other disease areas and was a member of Pfizer's global modelling committee between January 2017 and December 2017.
    - 20.3.1. It was agreed that as this declaration did not relate to a specific comparator product Dr Latimer could participate in this section of the meeting.
21. The Chair asked all NICE Staff to declare any relevant interests.
  - 21.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal cabozantinib for untreated metastatic renal cell carcinoma [ID1208].
22. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
  - 22.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cabozantinib for untreated metastatic renal cell carcinoma [ID1208].
23. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

24. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
25. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
26. The Chair then thanked the company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

## **Part 2 – Closed session**

27. Discussion on confidential information continued. This information was supplied by the company.
28. The Chair then thanked the Evidence Review Group representatives for their attendance, participation and contribution to the appraisal and they left the meeting.
29. The Committee continued to discuss the clinical and cost effectiveness of cabozantinib for untreated metastatic renal cell carcinoma [ID1208].
  - 29.1. The committee decision was based on consensus.
30. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

## **Date, time and venue of the next meeting**

Thursday 2 August 2018 at 10 Spring Gardens, London SW1A 2BU.